Table 1.

Key assumptions

Setting	Value
Perspective	Societal
Time horizon	40 years
Discounting of health and costsa	1.50%
Baseline cohort characteristics	Head-to-head clinical trial (SUSTAIN 7) [23]
Treatment effects	Head-to-head clinical trial (SUSTAIN 7) [23]
Treatment algorithm	Assume 3-year treatment duration then discontinue initial treatments and assume treatment with basal insulin
Macrovascular and mortality risk equations	UKPDS 82 [14]
Microvascular risk equations	WESDR, REP [29, 31]
Micro- and macrovascular complications cost	CADTH therapeutic review (2017) [39], Ward et al. (2014) [52]
Disutility weights	CADTH therapeutic review (2017) [39], Bagust and Beale (2005) [51]

CADTH Canadian Agency for Drugs and Technologies in Health, REP Rochester Epidemiology Project, UKPDS United Kingdom Prospective Diabetes Study, WESDR Wisconsin Epidemiological Study of Diabetic Retinopathy

^aThe discounting rate was chosen based on the Canadian Guidelines for the Economic Evaluation of Health Technologies [67]